DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
EBOS - 2 Eli Lilly - 1 Morgan - 1 Sean Wu - 1 Morgan Stanley's - 1 Health Organization's - 1 Morgan Stanley - 1 Chugai - 1
Top related locs:
Australia New Zealand U.S Asia Asia Pacific GLP WuXi China
Top related orgs:
Novo Nordisk - 1 Health - 1 WHO - 1 BMI - 1 WuXi AppTec - 1 Australian - 1 Hong Kong Stock Exchange - 1 China Health Care - 1

Search resuls for: "EBOS"


3 mentions found


☆ Want to cash in on the weight-loss drug boom? Morgan Stanley names 4 global stocks
  + stars: | 2024-02-01 | by ( Amala Balakrishner | ) www.cnbc.com   time to read: +4 min
Under-the-radar stock picks Morgan Stanley reckons the way to play the obesity theme in Asia is through names involved in GLP-1 drug development that "could find upside in burgeoning overseas markets." Calling it "top beneficiary as global demand for GLP-1 drugs significantly outpaces capacity," Morgan Stanley has an overweight rating on the stock. Morgan Stanley has an investment horizon of just over six months for WuXi AppTec and Innovent and over 12 months for Chugai and EBOS. Morgan Stanley's analysts estimate that worldwide sales of Orforglipron could hit $7 billion in 2023. Elsewhere, it sees opportunities for EBOS following the Australian government's approval for it to distribute obesity drugs.
Persons: Eli Lilly, Morgan, Sean Wu, Morgan Stanley's, Health Organization's, Morgan Stanley, Chugai, Goldman, EBOS, CNBC's Michael Bloom Organizations: Novo Nordisk, Health, WHO, BMI, WuXi AppTec, Australian, Hong Kong Stock Exchange, China Health Care, Goldman Sachs, Health Care Equity, Zealand ETF Locations: U.S, Asia, Asia Pacific, Australia, GLP, WuXi, China, Japan, New Zealand, Zealand
☆ NZ's EBOS dumps $2.4 billion Greencross buyout
  + stars: | 2023-11-21 | by ( Scott Murdoch | Thomson Reuters | Scott Murdoch Has Been A Journalist For More Than Two Decades Working For Thomson Reuters | ) www.reuters.com   time to read: +2 min
SYDNEY, Nov 22 (Reuters) - Australasian pharmaceutical distributor EBOS Group (EBO.NZ) has shelved a A$3.75 billion ($2.4 billion) deal to buy Australian vet chain Greencross, sending its shares down 7% during early trade on Wednesday. EBOS was due to pay A$3.75 billion to acquire Greencross, and was set to raise about A$2 billion as early as Wednesday, said one of the sources who could not be named discussing confidential information. The capital raising and associated buyout was put on hold because of weaker than expected demand from EBOS investors, the second source said. TPG and Greencross did not immediately respond to a request for comment. U.S. private equity TPG bought Greencross in 2019 and delisted it from the ASX in a deal worth A$669 million.
Persons: EBOS, Greencross, Scott Murdoch, Marguerita Choy, Stephen Coates Organizations: SYDNEY, EBOS, TPG Capital, TPG, Greencross, City Farmers, Liontown Resources, Thomson Locations: Australia, New Zealand, Albemarle, Sydney, Bengaluru
☆ This solar energy tech stock could surge more than 50%, Guggenheim says
  + stars: | 2023-05-09 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +2 min
Guggenheim says Shoals Technologies is poised to see big market share gains as demand grows. Shoals produces electric balance of system, or EBOS, components for solar energy projects. The solar energy tech company's adjusted first-quarter earnings and revenue topped analysts' estimates. "Demand is solid, but we think SHLS's success is also driven by market share gains. The analyst noted that Shoals hasn't been willing to offer any details on the magnitude of its other business efforts besides solar energy.
0 next >>
Total: 3